CEL-SCI Reports Clearance to Start Patient Enrollment in Phase 3 Cancer Immunotherapy Trial in Thailand

CEL-SCI Corporation

("CEL SCI" or the "Company") today announced that CEL-SCI is now cleared to start patient enrollment in Thailand in its ongoing Phase 3 trial with its investigational cancer immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary (not yet treated) head and neck cancer. Thailand is the 24th country to authorize CEL-SCI's Phase 3 trial for patient enrollment. "We have now completed enrollment of over 50% of the anticipated 880 patients in our Phase 3 trial and continue to expand the trial into more sites to increase the rate of enrollment. In the past month alone, we have added Spain and Italy as participating countries in our trial. We plan to have approximately 100 clinical centers around the world in about 25 countries screening and treating patients," stated CEL-SCI Chief Executive Officer Geert Kersten. As of May 31, 2015, 463 patients had been enrolled in the global Phase 3 study.